JV deal paves the Chinese way for MediciNova's acute asthma drug
This article was originally published in Scrip
Executive Summary
MediciNova has now finalised an agreement with Zhejiang Medicine for the establishment of a joint venture in China that will develop and commercialise one of the US firm's priority pipeline projects.